Page last updated: 2024-12-06

1-methylhypoxanthine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-methylhypoxanthine is a naturally occurring purine derivative found in various organisms. It is a structural analog of hypoxanthine, a crucial component of DNA and RNA. 1-methylhypoxanthine is known to exhibit biological activity, including potential roles in cell signaling and regulation. Research suggests it may be involved in processes such as neurotransmission, immune responses, and even cancer development. Its synthesis and metabolism are interconnected with cellular pathways involving purine biosynthesis and degradation. Researchers study 1-methylhypoxanthine to understand its precise mechanisms of action, its potential therapeutic applications, and its contributions to various physiological processes.'

1-methylhypoxanthine: increased concentration in rats bearing Yoshida Tumour [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-methylhypoxanthine : A methylhypoxanthine that is hypoxanthine with the methyl group at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID70765
CHEMBL ID1868124
CHEBI ID73959
SCHEMBL ID2115745
SCHEMBL ID1992699
MeSH IDM0086170

Synonyms (43)

Synonym
smr001557673
1-methylhypoxanthine
hypoxanthine, 1-methyl-
1125-39-9
nsc57902
nsc-57902
mls002667916 ,
4(3h)-quinazolinone, 2-(methylthio)-
inchi=1/c6h6n4o/c1-10-3-9-5-4(6(10)11)7-2-8-5/h2-3h,1h3,(h,7,8
1-methyl-1,9-dihydro-purin-6-one
1-methyl-7h-purin-6-one
1-methyl-1,9-dihydro-6h-purin-6-one
NCGC00246838-01
1-methyl-1h-purin-6(9h)-one
unii-lx5wq7jfr5
6h-purin-6-one, 1,7-dihydro-1-methyl-
lx5wq7jfr5 ,
nsc 57902
SCHEMBL2115745
AKOS005224355
6h-purin-6-one,1,9-dihydro-1-methyl-
1-methyl-1,7-dihydro-6h-purin-6-one
1-methyl-hypoxanthine
CHEBI:73959
1,7-dihydro-1-methyl-6h-purin-6-one
SCHEMBL1992699
1-methyl-1,7-dihydro-6h-purin-6-one #
KIQMCGMHGVXDFW-UHFFFAOYSA-N
CHEMBL1868124
DTXSID00150074
1-methyl-6,7-dihydro-1h-purin-6-one
1-methylhypoxanthin
1-methyl-1,9-dihydro-6h-purin-6-one (acd/name 4.0)
6h-purin-6-one, 1,7-dihydro-1-methyl- (9ci)
hypoxanthine, 1-methyl- (8ci)
2-(methylthio)-4(3h)-quinazolinone
1-methyl-6,9-dihydro-1h-purin-6-one
Q161649
6h-purin-6-one, 1,9-dihydro-1-methyl-
1,9-dihydro-1-methyl-6h-purin-6-one
STL439819
BS-51735
E84444
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
rat metaboliteAny mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
methylhypoxanthineAn oxopurine that is hypoxanthine with at least one methyl group substituted on to the ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency125.89203.548119.542744.6684AID743266
Guanine nucleotide-binding protein GHomo sapiens (human)Potency11.22021.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.74 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]